News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Panel Rejects VIVUS, Inc. (VVUS) Diet Drug


7/15/2010 2:31:44 PM

BOSTON (MarketWatch) -- An advisory panel of the U.S. Food and Drug Administration has refused to recommend Vivus Inc.'s /quotes/comstock/15*!vvus/quotes/nls/vvus (VVUS 12.11, 0.00, 0.00%) diet drug Qnexa for approval, according to Dow Jones Newswires. Citing various safety concerns, the panel narrowly rejected recommending the product, which had been shown in studies to be effective in helping overweight and obese people lose weight. While the FDA is not bound to the recommendations of its panels, it generally follows them. Shares of Vivus had been bid up considerably in recent months in anticipation of Qnexa's approval. Vivus shares were halted Thursday pending the outcome of the FDA meeting.

Read at Market Watch
Read at Business Week
Read at Wall Street Journal
Read at AP

comments powered by Disqus
 
 
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES